Trinity Biotech (NASDAQ:TRIB) Stock Price Crosses Above 50-Day Moving Average of $1.90

Share on StockTwits

Shares of Trinity Biotech plc (NASDAQ:TRIB) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.90 and traded as high as $2.52. Trinity Biotech shares last traded at $2.45, with a volume of 5,258 shares trading hands.

The stock has a market capitalization of $57.70 million, a PE ratio of 20.00 and a beta of 1.33. The business’s fifty day moving average price is $1.91. The company has a quick ratio of 2.74, a current ratio of 4.30 and a debt-to-equity ratio of 1.86.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.06). Trinity Biotech had a negative net margin of 23.81% and a positive return on equity of 3.20%. The firm had revenue of $22.03 million for the quarter.

A number of institutional investors and hedge funds have recently bought and sold shares of TRIB. Hunter Associates Investment Management LLC increased its position in Trinity Biotech by 10.8% in the 1st quarter. Hunter Associates Investment Management LLC now owns 1,078,610 shares of the company’s stock valued at $3,074,000 after acquiring an additional 104,928 shares in the last quarter. BlackRock Inc. acquired a new stake in Trinity Biotech in the 4th quarter valued at about $141,000. Finally, Lapides Asset Management LLC increased its position in Trinity Biotech by 2.1% in the 1st quarter. Lapides Asset Management LLC now owns 655,600 shares of the company’s stock valued at $1,868,000 after acquiring an additional 13,700 shares in the last quarter. Hedge funds and other institutional investors own 54.44% of the company’s stock.

About Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

Recommended Story: Ex-Dividend

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.